Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

Exclusion Criteria

• •Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%.
• •Body Mass Index (BMI) ≥ 40 kg/m².
• •Moderate to severe gastroesophageal reflux disease based on patient history.
• •Inability to comply with the treatment protocol or to understand the consent form.
• •Chronic Kidney Disease (CKD) Stage 4.
• •Aspartate aminotransferase (AST) \> 33 U/L or alanine aminotransferase (ALT) \> 36 U/L.
• •Active pregnancy.
• •Personal or family history of medullary thyroid carcinoma.
• •Personal or family history of multiple endocrine neoplasia type 2 syndrome.
• •Personal history of gastroparesis.
• •Personal history of diabetic retinopathy.
• •Known serious hypersensitivity, including anaphylaxis and angioedema, to Tirzepatide or any of its excipients.
• •Known serious hypersensitivity, including anaphylaxis and angioedema, to any GLP-1 receptor agonist class of therapies.
• •Concomitant treatment with GLP-1 receptor agonist therapy